Sugi Predict

Sugi Predict / Compounds / SCHEMBL4180763

SCHEMBL4180763

SCHEMBL4180763

Cc1c(C)n(CCCCCCN(C)Cc2ccc(N3CCOCC3)cc2)c2ccc3[nH]c(=O)cc(C(F)(F)F)c3c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ CASP1 P29466 2/20 0.38
▸ CASP7 P55210 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ AR P10275 9/20 0.35
▸ MAPT P10636 5/20 0.35
▸ NPSR1 Q6W5P4 3/20 0.35
▸ RECQL P46063 1/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ POLB P06746 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ NOD2 Q9HC29 1/20 0.33
▸ TERT O14746 1/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4177425 0.92 AR (0.44) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL4180397 0.88 ACHE (0.40) —
SCHEMBL4184325 0.84 AR (0.35) KDM4EALDH1A1HSD17B10ARNPSR1
SCHEMBL4172748 0.81 AR (0.43) AR
SCHEMBL4183868 0.81 AR (0.41) ARSMN1; SMN2
SCHEMBL4178956 0.79 AR (0.38) AR
SCHEMBL4183790 0.78 AR (0.39) AR
SCHEMBL4183123 0.78 BCHE (0.44) KDM4EALDH1A1NPC1
SCHEMBL4175644 0.77 AR (0.42) AR
SCHEMBL4170320 0.77 AR (0.47) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 — — US claimed
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 — — US disclosed
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 — — US disclosed
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227571-A1 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA KDM4E 1594/4885ALDH1A1 1408/4885CASP1 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.